Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses.

EBioMedicine - 1 Jun 2020

Raimondi Giulia, Mato-Berciano Ana, Pascual-Sabater Silvia, Rovira-Rigau Maria, Cuatrecasas Miriam, Fondevila Constantino, Sánchez-Cabús Santiago, Begthel Harry, Boj Sylvia F, Clevers Hans, Fillat Cristina

Abstract excerpt

BACKGROUND: Pancreatic patient-derived organoids (PDOs) are a well-established model for studying pancreatic ductal adenocarcinoma (PDAC) carcinogenesis and are potential predictors of clinical responses to chemotherapy. Oncolytic virotherapy is envisioned as a novel treatment modality for pancreatic cancer, and candidate viruses are being tested in clinical trials. Here, we explore the feasibility of using PDOs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Screening Assays, Antitumor

Share to Feasibility Studies

Share to Oncolytic Virotherapy

Share to Oncolytic Viruses

Share to Organoids

Share to Virus Internalization

Source

Open in PubMed Open full text

Identifiers

PMID: 32460166
DOI: 10.1016/j.ebiom.2020.102786
PMCID: PMC7251378

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses.PMID 32460166Read ↗

Pancreatic adenocarcinoma human organoids share structural and genetic features with primary tumorsSemantic proximity Read ↗

Combining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personalized treatmentSemantic proximity Read ↗

Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma TumorsSemantic proximity Read ↗

Patient-derived organoids guide personalized therapy for KRAS-mutant pancreatic cancer: synergistic MEK/mTOR inhibition and predictive chemotherapy responses.Semantic proximity Read ↗

Oncolytic virotherapy for pancreatic cancer.Semantic proximity Read ↗

The Diverse Applications of Pancreatic Ductal Adenocarcinoma OrganoidsSemantic proximity Read ↗

Establishing 3D organoid models from patient-derived conditionally reprogrammed cells to bridge preclinical and clinical insights in pancreatic cancerSemantic proximity Read ↗

Patient-derived Tumor Xenograft and Organoid Models Established from Resected Pancreatic, Duodenal and Biliary CancersSemantic proximity Read ↗

Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers.Semantic proximity Read ↗

Vesicular Stomatitis Virus as an Oncolytic Agent against Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Establishment and Thorough Characterization of Xenograft (PDX) Models Derived from Patients with Pancreatic Cancer for Molecular Analyses and Chemosensitivity TestingSemantic proximity Read ↗

Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and SolutionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.